🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the fight against drug-resistant strains of the pathogen, according to scientists.

A Global Challenge

Cases of gonorrhoea are on the rise globally, with estimates suggesting in excess of 82 million instances per year. Especially elevated rates are seen in the African continent and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely development in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The global health body has classified it as a "critical concern". Ongoing monitoring showed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Secure Clearance

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Scientists anticipate that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, gained clearance in the same week. This medication, which is additionally indicated for UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This milestone signifies a significant shift in the therapy of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Results and Worldwide Availability

According to findings published in a major medical journal, the new drug cured the vast majority of uncomplicated infections. This places it at an comparable level with the typical regimen, which involves an injection and a pill. The research enrolled nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have shared optimism. Access to a one-pill regimen such as this is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as vital to alleviate the strain of the illness for people and to stop the proliferation of untreatable gonorrhoea globally.